Format

Send to

Choose Destination
Cancer Res. 2015 Apr 1;75(7):1311-21. doi: 10.1158/0008-5472.CAN-14-2796. Epub 2015 Jan 29.

Interaction of BARD1 and HP1 Is Required for BRCA1 Retention at Sites of DNA Damage.

Author information

1
Department of Translational Oncology, St. Marianna University Graduate School of Medicine, Kawasaki, Japan. Division of Breast and Endocrine Surgery, Department of Surgery, St. Marianna University Graduate School of Medicine, Kawasaki, Japan.
2
Institute of Advanced Medical Science, St. Marianna University Graduate School of Medicine, Kawasaki, Japan.
3
Department of Translational Oncology, St. Marianna University Graduate School of Medicine, Kawasaki, Japan.
4
Department of Biochemistry, University of Washington, Seattle, Washington.
5
Divisions of Transgenic Animal Science, Advanced Science Research Center, Kanazawa University, Kanazawa, Japan.
6
Division of Breast and Endocrine Surgery, Department of Surgery, Hyogo College of Medicine, Hyogo, Japan.
7
Department of Translational Oncology, St. Marianna University Graduate School of Medicine, Kawasaki, Japan. Division of Breast and Endocrine Surgery, Department of Surgery, St. Marianna University Graduate School of Medicine, Kawasaki, Japan. to@marianna-u.ac.jp.

Abstract

Stable retention of BRCA1/BARD1 complexes at sites of DNA damage is required for the proper response to DNA double-strand breaks (DSB). Here, we demonstrate that the BRCT domain of BARD1 is crucial for its retention through interaction with HP1. In response to DNA damage, BARD1 interacts with Lys9-dimethylated histone H3 (H3K9me2) in an ATM-dependent but RNF168-independent manner. This interaction is mediated primarily by HP1γ. A conserved HP1-binding motif in the BARD1 BRCT domain directly interacted with the chromoshadow domain of HP1 in vitro. Mutations in this motif (or simultaneous depletion of all three HP1 isoforms) disrupted retention of BARD1, BRCA1, and CtIP at DSB sites and allowed ectopic accumulation of RIF1, an effector of nonhomologous end-joining, at damaged loci in S-phase. UNC0638, a small-molecule inhibitor of histone lysine methyltransferase (HKMT), abolished retention and cooperated with the PARP inhibitor olaparib to block cancer cell growth. Taken together, our findings show how BARD1 promotes retention of the BRCA1/BARD1 complex at damaged DNA sites and suggest the use of HKMT inhibitors to leverage the application of PARP inhibitors to treat breast cancer.

PMID:
25634209
PMCID:
PMC5003120
DOI:
10.1158/0008-5472.CAN-14-2796
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center